Lantern Pharma (NASDAQ: LTRN), an artificial intelligence company focused on transforming oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. This presentation underscores Lantern's commitment to leveraging its proprietary AI and machine learning platform, RADR®, to accelerate the development of cancer therapies and address the high costs and lengthy timelines associated with traditional drug development.
The company's RADR platform integrates over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms, enabling it to solve complex challenges in oncology drug development. This AI-driven approach has allowed Lantern to build a diverse pipeline targeting both solid tumors and blood cancers, including an antibody-drug conjugate (ADC) program. Lantern's lead programs include a Phase 2 clinical trial and multiple Phase 1 studies, with the combined annual market potential of its pipeline estimated to exceed $15 billion.
Investors and industry observers will be closely watching the presentation for updates on Lantern's clinical progress and strategic direction. The ThinkEquity Conference provides a platform for emerging growth companies to connect with institutional investors, and Lantern's participation highlights its efforts to secure funding and partnerships to advance its therapies. The company's ability to use AI to streamline drug development could have significant implications for the oncology field, potentially bringing life-changing treatments to hundreds of thousands of cancer patients worldwide.
For those unable to attend in person, additional details about Lantern Pharma and its pipeline are available in the company's newsroom at https://ibn.fm/LTRN. The press release with further information can be accessed at https://ibn.fm/QSF41.
Lantern Pharma's focus on AI-driven drug discovery represents a paradigm shift in oncology, offering the potential to reduce development costs and accelerate the delivery of effective therapies. As the company continues to advance its pipeline, its presentation at the ThinkEquity Conference will be a key opportunity to gauge investor sentiment and the market's reception of its innovative approach.
